ResMed added to APAC Conviction List at Goldman Sachs
Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company.
Fiscal Year: July - June
ResMed Inc. (RMD), listed on the NYSE, has a market capitalization of $29.04B. As of Jul 02, 2026, the stock is trading at $201.10 per share@else an unavailable price , offering investors a clear view of its current market value. ResMed Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 19.39, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. ResMed Inc. also offers a dividend yield of 1.19%, making it an attractive option for income-focused investors who seek regular dividends.
DCF analysis data is not yet available for ResMed Inc. (RMD). The fair value estimate will be displayed once sufficient analyst forecast data is collected.
The proprietary SS Score for ResMed Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for ResMed Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for ResMed Inc. is 16.56, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, ResMed Inc. (RMD) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether ResMed Inc. (RMD) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of ResMed Inc. (RMD) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of ResMed Inc.. To access the full SS Score, consider upgrading your subscription.
ResMed Inc. is a significant player in the industry sector, with a market capitalization of $29.04B and a competitive P/E ratio of 19.39. Investors should compare these metrics with industry peers to gauge whether ResMed Inc. is outperforming or underperforming within its sector.
Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects continuous airway pressure therapy patient growth for the company.
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, ...
KeyBanc lowered the firm’s price target on ResMed (RMD) to $266 from $290 and keeps an Overweight rating on the shares. Last week’s attendance at the SLEEP APSS Meeting in…
Morgan Stanley analyst David Bailey downgraded ResMed (RMD) to Equal Weight from Overweight with a price target of $230, down from $286. The company has posted annual earnings growth of…
Citi lowered the firm’s price target on ResMed (RMD) to $270 from $340 and keeps a Buy rating on the shares. The says the company’s fundamentals are intact despite the…
Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition a...
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the...
Resmed (RMD) and Oura announced they are partnering to expand access to sleep health education and pathways to care. By connecting consumer-generated wellness insights with Resmed’s sleep health resou...
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world...
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and…
Stifel lowered the firm’s price target on ResMed (RMD) to $235 from $265 and keeps a Hold rating on the shares.
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
Resmed (RMD) announced that Brett Sandercock, CFO, plans to retire effective May 4. After conducting a search, Aaron Bloomer has been appointed as his successor. Bloomer joinsResmedfrom Exact Sciences...
Reports Q3 revenue $1.43B, consensus $1.42B. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined ...
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett...
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%...
KeyBanc lowered the firm’s price target on ResMed (RMD) to $290 from $302 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying…
JPMorgan initiated coverage of ResMed (RMD) with an Overweight rating and A$37.60 price target The firm says ResMed is the global leader in the obstructive sleep apnea market. While therapeutics,…
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.